HCA Healthcare is the subject of a consensus analyst target price report, with 24 analysts setting a USD 467.61 average target as of October 17, 2026. This valuation represents a slight premium of 1.54% over the stock's trading price of USD 460.51 recorded on October 19, 2026. The article highlights that this consensus figure serves as a benchmark for investors to compare against the company's upcoming third-quarter earnings call scheduled for October 27, 2026. The stock is currently listed on the NYSE with a market capitalization of USD 99.7 billion and trades at a P/E ratio of 15.33. The company recently posted a modest gain of 0.36%, trading within a 52-week range that spans from USD 353.99 to USD 556.52. While the current price sits significantly below its yearly high, it remains well above the 52-week low, indicating a stable but not peak valuation relative to its historical performance. The report provides specific financial metrics including a quarterly dividend of USD 0.78 and a dividend yield of 0.70% as of late October 2026. The article notes that the next major catalyst for the stock will be the release of Q3 operating results, which analysts will use to validate whether the current consensus target remains appropriate given the company's operational performance. Contextual data includes comparisons to peers such as Tenet Healthcare and Universal Health Services, though the primary focus remains on HCA's specific valuation metrics and upcoming earnings event. The text emphasizes that the October 27 earnings call is the critical date for determining if the stock can justify its current multiple or if the consensus target needs adjustment based on reported revenue and margins.